AWARD NUMBER: W81XWH-10-1-0420

TITLE: Synthesis of PSA Inhibitors as SPECT- and PET-Based Imaging Agents for Prostate Cancer

PRINCIPAL INVESTIGATOR: Maya Kostova, Ph.D.

CONTRACTING ORGANIZATION: Johns Hopkins University Baltimore, MD 21231

REPORT DATE: June 2011

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTAL	ION PAGE			OMB No. 0704-0188		
data needed, and completing and reviewing this collection of this burden to Department of Defense, Washington Headqu	of information. Send comments regar arters Services, Directorate for Infor any other provision of law, no persor	arding this burden estimate or any mation Operations and Reports in a shall be subject to any penalty f	y other aspect of th (0704-0188), 1215	searching existing data sources, gathering and maintaining the iis collection of information, including suggestions for reducing Jefferson Davis Highway, Suite 1204, Arlington, VA 22202- vith a collection of information if it does not display a currently		
1. REPORT DATE	2. REPORT TYPE	ALOO.		3. DATES COVERED		
1 June 2011	Annual Summary			1 Jun 2010 – 31 May 2011		
4. TITLE AND SUBTITLE	7 timadi Gammary			5a. CONTRACT NUMBER		
Synthesis of PSA Inhibitors as SPECT- and PET-Based Imaging Agents for Prostate Cancer			i i ootato	5b. GRANT NUMBER W81XWH-10-1-0420		
				5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)			:	5d. PROJECT NUMBER		
Maya Kostova, Ph.D.				5e. TASK NUMBER		
E-Mail: mkostov1@jhmi.edu				5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21231			8. PERFORMING ORGANIZATION REPORT NUMBER			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)			
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATE Approved for Public Release; Distrib						
13. SUPPLEMENTARY NOTES						
produced by the normal epithelial coconcentrations, in the extracellular f cancers. Even though the expression not well established. To aid the better	ells of the prostate. His luid) are produced by on of PSA is closely refer understanding of Poared a library of novelecular hydrogen bonchibitors to incorporate participate in halogen	gh levels of enzyma androgen depender lated to the cancer SA role in prostate of the peptidyl boronic and ds and/or disulfide the ded bromopropylglyce bond formation. T	atically activent as well a progression cancer devected based in bonds. To poine group.	s androgen independent prostate its role in the cancer pathobiology is elopment and to expand the number of hibitors. Protease inhibitors commonly repare more selective inhibitors we This allowed the inhibitors to reach		
15. SUBJECT TERMS Prostate cancer, PSA inhibitors, bor	onic acids, peptidomi	metics, serine prote	ase inhibition	onocular reflex, autism		
16. SECURITY CLASSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBE OF PAGES	R 19a. NAME OF RESPONSIBLE PERSON USAMRMC		

UU

11

a. REPORT

b. ABSTRACT

U

c. THIS PAGE

U

**19b. TELEPHONE NUMBER** (include area code)

Form Approved

# **Table of Contents**

	<u>Page</u>
Introduction	4
Body	4
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusion	9
References	9
Appendices	10

#### Introduction

Prostate cancer is the most common cancer among men of all races and the second leading cause of cancer death, according to the CDC. Nearly 1 in 6 men will develop prostate cancer in their lifetime and as a result about 30,000 of them will die this year in US alone (1, 2). Generally, inflammatory processes in the prostate are related to higher PSA production. While a small percentage of poorly differentiated prostate cancers produce low levels of PSA, the majority (>95%) continue to produce high levels that can be readily measured in the blood of patients as the disease progresses from hormone sensitive to castration resistant to chemotherapy refractory (3-8). There are two major clinical problems associated with the treatment of metastatic prostate cancer. First, all men undergoing androgen ablation, eventually relapse and no longer respond to hormone treatment. Therefore, there is an urgent need for more effective therapies for patients with metastatic disease. In addition, the clinical development of such novel therapies is limited by the inability to adequately measure the response of prostate cancer metastases in the majority of patients. The lack of sensitive imaging techniques limits not only the followup of patients' response to therapy but also the detection of prostate cancer metastases. The development of new therapeutics is also highly dependent on the existence of selective biomarkers and proven imaging techniques. Therefore, intervention at this level and efforts resulting in decrease of the active PSA may subsequently slow down the advancement of the disease and may become an efficient way to control the cancer progression. Based on the PSA specific cleavage map and earlier identified substrates we developed potent and selective PSA inhibitors with inhibition constant in the nanomolar range.

# **Body**

In partial fulfillment of the goals of this proposal the following tasks outlined in the approved Statement of Work are completed.

**Task 1:** Synthesize a series of boronic acid - peptide conjugates as PSA inhibitors and characterize them for their ability to selectively bind to and inhibit the enzymatic activity of PSA vs. other extracellular proteases. (Completed)

1. Synthesis, purification and characterization of peptidyl boronic acids:

Using the synthetic schemes suggested in the proposal we were able to prepare phenylalanine boronic acid. The final product was achieved using commercially available starting materials and well studied protocols developed by Matteson and Winssinger (9, 10).

Scheme 1. Synthesis of phenylalanine boronic acid and structure of bromopropylglycine boronic acid

We were unable to prepare methionine and glutamine derivatives of boronic acids due to synthetic difficulties. However, we wanted to compare aromatic vs. aliphatic residue for a better fit for the active site. Thus, bromopropylglycine boronic acid was selected because it somewhat mimics hydrophobic residues like Leu and Nle, which have shown optimal binding due to their medium length hydrocarbon chains. The polar character of the bottom of the pocket prompted us to select polar ending for the amino acid residue such as bromine.

All final products were purified using reverse phase semi-preparative HPLC. The products were characterized by <sup>1</sup>H and <sup>13</sup>C NMR on a 400 MHz Bruker Advance NMR Spectrometer. Mass spectra were measured on a Bruker 3000 Esquire Mass Spectrometer equipped with ESI. All synthetic protocols and structural characterizations for the boronic acids and their precursors are reported in the Appendices section.

2. Synthesis, purification and characterization of inhibitors containing other natural and unnatural amino acids and/or peptidomimetics in P4:

Eleven peptidyl boronic acids were successfully prepared according to the suggested procedure described in the grant proposal. The peptide moieties were prepared on a solid phase support using Apex 396 peptide synthesizer. The products were obtained using standard Fmoc protocol, starting with preloaded Fmoc-Nle-OH onto a 2-ClTrt resin. The exact protocol is described in the Appendices section.

Scheme 2. Synthesis of peptidyl botonic acid

Inhibitors containing Alanine, Phenylalanine and Naphthylalanine at P4 were also prepared and tested. Replacing the second serine with a hydrophobic amino acid allowed us to manipulate the lypophilicity of the peptides with expectation of delaying the clearance.

$$H_{2}N$$

$$H_{2}N$$

$$H_{2}N$$

$$H_{3}N$$

$$H_{4}N$$

$$H_{5}N$$

$$H$$

Scheme 3. General structure of peptide boronic acid and lipophilic amino acid substituents at P4

The final products were purified on a semi-prep RP-HPLC column from Phenomenex: Luna C18, particle size  $10~\mu$ , 250~x~10~mm. The HPLC used for the analysis and purification was equipped with photodiode array detector and purchased from Waters (Milford, MA).

Of the HPLC methods developed for the purification of the peptides the following two had the best purification conditions:

- <sup>a</sup>- HPLC method: gradient of 15-90% buffer B over 25 min at 5 mL/min
- b- HPLC method: gradient of 10-95% buffer B over 25 min at 5 mL/min

Buffer A = 0.1% TFA in 5% MeOH and 95% water

Buffer B = 0.1% TFA in MeOH

The retention times (R<sub>t</sub>, min) of all products are reported in Table 1.

### 3. Ki determination for PSA inhibition:

Candidate inhibitors were incubated at different concentrations with enzymatically active PSA (Calbiochem) in the presence of the PSA substrate Mu-SRKSQQY-AMC ( $K_m$ = 140  $\mu$ M) (California Peptides). Change in fluorescence due to proteolytic release of AMC was followed using a 96 well fluorometric plate reader. The velocity of each reaction (change in RFU/time) was determined and plotted vs. concentration of the inhibitors.




Figure 1. Time progression curves for the inhibition of PSA by Z-SSKn(boro)Br over a range of concentrations

The inhibition constant  $(K_i)$  of each compound was determined by solving the equation:  $K_i = 1/\text{slope} \times 1/(1+[S]/K_m)$ , where the slope is obtained from a linear plot of  $V_o/V_i$  - 1 vs. [I]. The reciprocal of the slope is also equal to the  $K_{i(app)}$ , apparent inhibition constant. [S] = substrate concentration, [I] = inhibitor concentration,  $K_m = \text{Michaelis constant}$ ,  $V_o = \text{rate of substrate hydrolysis in the absence of inhibitor, and } V_i = \text{rate in the presence of inhibitor.}$  The  $K_i$  values for PSA inhibition are reported in Table 1.




Figure 2. Linear plot of V<sub>o</sub>/V<sub>i</sub> - 1 vs. [I] for Z-SSKn(boro)Br used for calculation of K<sub>i</sub>

4. Selectivity evaluation of individual inhibitors with  $K_i$  for PSA of <200 nM against extracellular proteases:

The inhibitors were assayed for their specificity for PSA relative to chymotrypsin using the method described above. Suc-AAPF-AMC (Sigma, USA) was used as a substrate for Chymotrypsin (Sigma, USA). The determined inhibitory constants for Chymotrypsin are reported in Table 1. All assays were performed in triplicate and the average value at each point was plotted and reported.

Inhibitor	m/z, [M+H-18] <sup>+</sup> , [M+H] <sup>+</sup>	R <sub>t</sub> , min	K <sub>i</sub> (nM) PSA inhibition	K <sub>i</sub> (nM) Chymotrypsin inhibition
Z-SSKn(boro)F	697.0	$25.6^{a}$	164.503	18.108
Z-SSKn(boro)Br	729.0	$24.2^{a}$	24.228	196.882
Ahx-SSQn(boro)L	642.1, 660.0	$21.9^{b}$	43.053	137.837
Ahx-SQn(boro)F	589.4, 607.4	$20.9^{a}$	22.01	3.765
Ahx-SQn(boro)Br	620.9, 638,9	$19.0^{a}$	302.096	250.575
Ahx-ASQn(boro)F	660.0, 678.0	$23.1^{\rm b}$	310.286	36.22
Ahx-ASQn(boro)Br	690.1, 708.3	$20.7^{a}$	52.11	165.921
Ahx-FSQn(boro)F	736.6, 754.5	$24.5^{a}$	61.484	0.135
Ahx-FSQn(boro)Br	768.5, 786.5	$22.9^{a}$	72.288	580.724
Ahx-NaphSQn(boro)F	800.0, 818.0	$24.6^{a}$	228.782	7.214
Ahx-NaphSQn(boro)Br	831.9, 849.8	24.9 <sup>a</sup>	102.463	505.676

<sup>&</sup>lt;sup>a</sup>- HPLC method: gradient of 15-90%, 0.1% TFA in MeOH over 25 min at 5 mL/min

Table 1. Chemical structures, exact masses detected by ESI/MS, HPLC retention times and inhibition constants of PSA inhibitors

**Task 2:** Selected PSA inhibitors will be labeled with I-125 at the amino terminus. The pharmacokinetics of these inhibitors will be evaluated *in vivo* in animals bearing isogenic PSA positive and negative prostate cancer xenografts. (Experiment in progress)

b- HPLC method: gradient of 10-95%, 0.1% TFA in MeOH over 25 min at 5 mL/min

1. Optimization of HPLC purification method for each labeled inhibitor:

An optimal solvent condition for analytical RP-HPLC purification is being determined based on the polarity of the products. For this task non-radioactive iodine labeled products are being prepared. For the cold runs N-hydroxysuccinimidyl-4-iodobenzoate (SIB) was prepared in one step according to procedure reported by Vaidyanathan (11). The following synthetic scheme is being used to prepare the precursor for radiolabeling.

Scheme 4. Synthesis of 125I-SIB for radioiodination of peptidyl boronic acids

The products were purified on analytical RP-HPLC column from Phenomenex: Luna C18, particle size 5  $\mu$ , 150 x 4.60 mm.

HPLC method: gradient of 30-100% buffer B over 16 min at 1.25 mL/min, then gradient of 0-70% buffer A over 12 min at the same flow rate.

Buffer A = 0.1% TFA in 5% acetonitrile and 95% water

Buffer B = 0.1% TFA in acetonitrile

The following retention times were determined: iodobenzoic acid - 10.57 min, SIB - 12.54 min, and Sn-precursor - 24.40 min.

# **Key Research Accomplishments**

- Synthesized, purified and characterized a library of eleven peptidyl boronic acids.
- Explored the inhibition potential of (boro)Bpg vs. (boro)Phe and compared aromatic vs. aliphatic substituent of the boronic acid.
- Examined the importance of serine at P4 and the possibility of replacing it with hydrophilic amino acids, such as alanine, phenylalanine and naphthylalanine.
- Evaluated the products as inhibitors of PSA by following the enzyme kinetics.
- Evaluated the selectivity of PSA inhibitors by determining the inhibitory constants for chymotrypsin.
- Prepared the precursors for radiolabeling and the non-radioactive iodine carrier and established their HPLC purification conditions.

### **Reportable Outcomes**

Based on the conducted research and results from the study the PI had submitted two abstracts and attended two conferences:

- "Novel peptidyl boronic acid based inhibitors of PSA", M. B. Kostova, D. M. Rosen, S. R. Denmeade at 240<sup>th</sup> ACS National Meeting, Boston, MA, August 2010
- "Synthesis and biological evaluation of selective inhibitors of prostate-specific antigen", M. B. Kostova, D. M. Rosen, S. R. Denmeade at CDMRP IMPaCT Conference, Orlando, FL, March 2011

The PI also co-authored the following article:

• LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem. 2010; 391:333-43.

The PI has also presented the findings at our local Chemical Therapeutics program meetings at Johns Hopkins University.

#### Conclusion

Base on previously published data of peptidyl aldehydes we were able to create a new library of drug candidates with improved inhibitory properties. The presence of bromine at the end of the side chain of the active site residue allows for halogen bond formation. The formation of such halogen bonds provides a unique base for inhibitor - enzyme recognition, therefore we were able to prepare more specific and selective inhibitors of PSA. Also, the results of this study revealed additional information about the structure of the active site of PSA and the structural requirements of a nanomolar inhibitor.

### References

- 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin, 2007, 57, 43-66
- 2. Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer: Improvement in quality and duration of life. Expert Rev Anticancer Ther, 2008, 8 (2), 269-81
- 3. Denmeade SR, Lou W, Malm J, Lovgren J, Lilja H, Isaacs JT. Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate Specific Antigen. Cancer Res, 1997, 57, 4924-4930
- 4. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of Enzymatically Active Prostate-Specific Antigen (PSA) in the Extracellular Fluid of Primary Human Prostate Cancers and Human Prostatic Cancer Xenograft Models. Prostate, 2001, 48, 1-6
- 5. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of Latent Protease Function of Pro-HK2, but not Pro-PSA, Involves Auto-Processing. Prostate, 2001, 48, 122-126
- 6. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation Between Androgen Responsiveness for Malignant Growth vs. Expression of Prostate Specific Differentiation Markers PSA, hK2 and PSMA in Human Prostate Cancer Models. Prostate, 2003, 54, 249-257
- 7. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-Specific Antigen (PSA) Protein Does Not Affect Growth of Prostate Cancer Cells In Vitro or Prostate Cancer Xenografts In Vivo. Prostate, 2003, 56, 45-53
- 8. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate, 2006, 67, 312-329
- 9. Matteson DS, Michnick TJ, Willett RD, Patterson CD. [(1R)-1-Acetamido-3-(methylthuio)propyl] Boronic Acid and the X-ray Structure of its Ethylene Glycol Ester. Organometallics, 1989, 8, 726-729
- 10. Debaene F, Da Silva JA, Pianowski Z, Duran FJ, Winssinger N. Expanding the Scope of PNA-Encoded Libraries: Divergent Synthesis of Libraries Targeting Cysteine, Serine and Metalloproteases as Well as Tyrosine Phosphatases. Tetrahedron, 2007, 63, 6577-6586
- 11. Vaidyanathan G, Zalutsky MR. Preparation of N-succinimidyl 3-[I\*]iodobenzoate: an Agent for the Indirect Radioiodination of Proteins. Nature protocols, 2006, 2, 707-713
- 12. Matteson DS, Sadhu KM. R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state

- analog for chymotrypsin. Journal of the American Chemical Society. 1981, 103, 5241-5242
- 13. Matteson DS, Sadhu, KM. Synthesis of 1-Amino-2-phenylethane-1-boronic Acid Derivatives. Organometallics, 1984, 2, 1529-1535
- LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and Selective Peptidyl Boronic Acid Inhibitors of the Serine Protease Prostate-Specific Antigen. Chemistry and Biology, 2008, 15, 665-674

## **Appendices**

- (+)-Pinanediol Phenylmethyl-1-boronate (2). To a solution of 1 g (7.36 mmol) benzyl boronic acid 1 in 80 mL of ether were added 1 eqv. of (+)-pinanediol (1.25 g) and 3 g of MgSO<sub>4</sub>. The solution was stirred for 2-3 days and the product formation was followed by NMR. The reaction mixture was filtered out and the organic layer was washed with satd. NaHCO<sub>3</sub> (20 mL x 2) and brine (20 mL x 2). After drying the organic layer was concentrated under low pressure and kept under high vacuum overnight to yield 85% colorless oil. The product was used for the next step without purification.  $^{1}$ H NMR (CDCl<sub>3</sub>): δ 0.85 (s, 3H), 1.07 (d, J = 11.0, 1H), 1.28 (s, 3H), 1.39 (s, 3H), 1.9 (m, 2H), 2.05 (m, 1H), 2.2 (m, 1H), 2.28 (m, 1H), 2.35 (s, 2H), 4.29 (dd, J = 8.9, 2.1, 1H), 7.16-7.34 (m, 5H);  $^{13}$ C NMR (CDCl<sub>3</sub>): δ 23.95, 26.50, 28.31, 28.68, 36.22, 38.36, 39.48, 51.31, 78.34, 85.89, 110.64, 124.84, 128.47, 129.13, 138.86; MS (ESI) m/z 288.0 [M+H<sub>2</sub>O]<sup>+</sup>, 293.1 [M+Na]<sup>+</sup>.
- (+)-**Pinanediol** (*S*)-1-chloro-2-phenylethaneboronate (3).(12, 13) In a three-neck flask equipped with thermometer, a solution of 10 mL of freshly distilled THF and 1.3 mL of DCM was cooled to -100°C (in etahnol/liquid nitrogen bath) under argon atmosphere. Chilled at -78°C n-BuLi (8.6 mmol; 2.5 M in hexane) was added via syringe by running it down the cold wall of the reaction flask over a period of 15 min. White precipitate of LiCHCl<sub>2</sub> was formed and after 10 min of stirring, cold solution of 0.38 g (1.4 mmol) of (+)-pinanediol phenylmethyl-1-boronate 2 in 2 mL of dry THF was added. After 10 min of stirring at -100°C, 8 mL of ZnCl<sub>2</sub> solution (0.5 M in THF) were added. The solution was stirred overnight and the temperature was allowed to rise to room temperature. The reaction mixture was evaporated and re-dissolved in hexane. The organic phase was washed with satd. NH<sub>4</sub>Cl, water, and brain, then dried and concentrated to give about 80% crude product as colorless oil. The product was used for the next step without purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.84 (s, 3H), 1.08 (d, J = 11.2, 1H), 1.28 (s, 3H), 1.36 (s, 3H), 1.90 (m, 2H), 2.08 (m, 1H), 2.19 (m, 1H), 2.35 (m, 1H), 3.11 (dd, J = 8.6, 13.7, 1H), 3.23 (dd, J = 7.9, 13.9, 1H), 3.68 (dd, J = 8.5, 7.8, 1H), 4.46 (dd, J = 2.0, 11.3, 1H), 7.20-7.35 (m, 5H); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  23.95, 26.22, 27.02, 28.33, 29.71, 35.15, 38.24, 39.35, 40.45, 51.22, 78.56, 86.79, 126.72, 126.75, 128.35, 129.20, 129.24, 138.42. MS (ESI) m/z 283.0, [M-Cl+H]<sup>+</sup>.
- (+)-Pinanediol (*R*)-1-(N-Bis(trimethylsilyl)amino)-2-phenylethane-1-boronate (4). An oven dried flask containing 5 mL of freshly distilled THF was cooled to -78°C and flushed with argon. After addition of 7.2 mL (1.25 eqv.) of lithium bis(trimethylsilyl)amide, LiN(SiMe<sub>3</sub>)<sub>2</sub> (1 M solution in THF) the contents of the flask were stirred for 10 min. Crude boronic ester 3 (1.8 g, 5.6 mmol) was dissolved in 10 mL of THF and added dropwise. The reaction mixture was stirred overnight and allowed to warm to room temperature. The resulting solution was concentrated under reduced pressure, reconstituted in 25 mL of DCM and filtered through Celite. The organic layer was dried with MgSO<sub>4</sub> and evaporated to give 2.5g of crude product as light brown oil with m/z 444, corresponding to [M+H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.09 (s, 18H), 0.83 (s, 3H), 0.97 (d, J = 10.6, 1H), 1.27 (s, 3H), 1.38 (s, 3H), 1.82 (m, 2H), 2.01 (m, 1H), 2.12 (m, 1H), 2.30 (m, 1H), 2.67 (m,1H), 2.74 (dd, J = 13.2, 7.2, 1H), 3.05 (m, 1H), 4.30 (dd, J = 8.6, 2.1, 1H), 7.20-7.32 (m, 5H).

(+)-Pinanediol (*R*)-1-Amino-2-phenylethane-1-boronate trifluoroacetate salt (5). 0.5 g of the crude compound 4 (1.1 mmol) were dissolved in 10 mL of ethyl ether and cooled down to 0°C. To the mixture was added TFA (0.25 mL, 3.3 mmol) and the reaction was allowed to stir for 3h. The TFA salt crashed out of solution and was filtered. The final product was washed three times with cold ethyl ether resulting in white powder with 73% yield (0.34 g).  $^{1}$ H NMR (methanol-d4): δ 0.89 (s, 3H), 1.11 (d, J = 10.8, 1H), 1.34 (s, 3H), 1.42 (s, 3H), 1.93 (m, 2H), 2.06 (m, 1H), 2.26 (m, 1H), 2.43 (m, 1H), 3.03 (dd, J = 8.1, 14.0, 1H), 3.11 (dd, J = 6.4, 14.2, 1H), 3.25 (dd, J = 6.5, 8.0, 1H), 4.50 (d, J = 8.2, 1H), 7.30-7.37 (m, 5H);  $^{13}$ C NMR (methanol-d4): δ 24.25, 27.37, 27.49, 28.81, 35.92, 36.46, 39.38, 40.77, 52.40, 80.33, 89.14, 128.58, 130.00, 130.35, 137.88; MS (ESI) m/z 300.1, [M] $^{+}$ .

General Method for Synthesis of Peptidyl Boronic Acids. The desired N-terminus protected peptide Boc-Ahx- or Z- (1 mmol) was dissolved in 50 mL of CH<sub>2</sub>Cl<sub>2</sub> and the solution was cooled in icebath. HOBt (1.5 mmol, 0.229 g) and EDC (1.5 mmol, 0.288 g) were added to the mixture and stirred for 15 min. Boronic acid pinanediol ester (1 eqv.) was added and after 10 min of stirring at 0°C N-methylmorpholine (2 mmol, 0.23 mL) was added. The solution was stirred overnight and the temperature was allowed to warm slowly to room temperature. The reaction mixture was washed with water x 2, and brine x 2. The organic layer was dried with MgSO<sub>4</sub> and evaporated to dryness to yield crude protected peptide in 95-97% yield. The resulting white powder was then stirred with 95% TFA in water to remove all of the peptide side chain protecting groups. After 1h of stirring at room temperature the reaction was concentrated in vacuo and resulting residue was resuspended in a 1:1 mixture of ethyl ether/water (40 mL). Phenyl boronic acid (0.305 g, 2.5 mmol) was then added to remove the (+)-pinanediol protecting group. The deprotection was allowed to go overnight at room temperature. The aqueous layer containing the fully deprotected peptidyl boronic acid was washed with ethyl ether (30 mL, 3 x) and lyophilized. The product was purified by HPLC and the resulting white powder was characterized by MS.

**Enzyme assays**. Peptidyl boronic acids were dissolved in DMSO at 20 mM. Stock solutions could be stored at -20°C and were stable for one year. More diluted solutions were prepared as necessary. The activity of the inhibitors was determined by monitoring the change of fluorescence of AMC substrate (ex. 370 nm; em. 465 nm) due to hydrolysis by PSA. Product formation was followed over 30 min. The  $K_m$  for the substrate Mu-SRKSQQY-AMC was previously determined (14) to be 140 μM. Kinetic measurements were done in triplicate and run at 37°C in PSA buffer (50 mM TRIS, 100 mM NaCl, pH 7.8). Reactions were performed on 96-well plate where the final concentration of PSA was 2.5 μg/mL (2 nM active PSA) and the substrate was 300 μM. The assay mixture contained 100 μL of buffer, peptidyl boronic acid in DMSO (20 μL), PSA solution (20 μL) and Mu-SRKSQQY-AMC in buffer (60 μL). The following concentrations of inhibitors were employed for the assay: 50, 25, 12.5, 6.25, 3.1, 1.56, 0.78, 0.39, 0.19, 0.098, 0.049 and 0.0244 μM.

Selectivity of the compounds was determined by screening the products against chymotrypsin. Chymotrypsin assays were performed by monitoring the fluorescence of Suc-AAPF-AMC substrate at the above described conditions. The  $K_m$  value of chymotrypsin for the substrate Suc-AAPF-AMC was determined to be 14  $\mu M$ . Reactions were performed on 96-well plate where the final concentration of chymotrypsin was 2 nM and the substrate was 25  $\mu M$ . The assay mixture contained peptidyl boronic acid in DMSO (20  $\mu L$ ), Suc-AAPF-AMC in PSA buffer (90  $\mu L$ ) and chymotrypsin solution (90  $\mu L$ ). The chymotrypsin substrate solution was added last to each assay solution and the kinetic data was collected immediately.